GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » EV-to-FCF

Zhaoke Ophthalmology (HKSE:06622) EV-to-FCF : 1.16 (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zhaoke Ophthalmology's Enterprise Value is HK$-532.93 Mil. Zhaoke Ophthalmology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-458.22 Mil. Therefore, Zhaoke Ophthalmology's EV-to-FCF for today is 1.16.

The historical rank and industry rank for Zhaoke Ophthalmology's EV-to-FCF or its related term are showing as below:

HKSE:06622' s EV-to-FCF Range Over the Past 10 Years
Min: -0.7   Med: 1.02   Max: 1.18
Current: 1.18

During the past 5 years, the highest EV-to-FCF of Zhaoke Ophthalmology was 1.18. The lowest was -0.70. And the median was 1.02.

HKSE:06622's EV-to-FCF is ranked better than
64.91% of 379 companies
in the Biotechnology industry
Industry Median: 8.31 vs HKSE:06622: 1.18

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-06), Zhaoke Ophthalmology's stock price is HK$1.49. Zhaoke Ophthalmology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.776. Therefore, Zhaoke Ophthalmology's PE Ratio for today is At Loss.


Zhaoke Ophthalmology EV-to-FCF Historical Data

The historical data trend for Zhaoke Ophthalmology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhaoke Ophthalmology EV-to-FCF Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -1.25 0.22 -1.79

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only -1.25 - 0.22 - -1.79

Competitive Comparison of Zhaoke Ophthalmology's EV-to-FCF

For the Biotechnology subindustry, Zhaoke Ophthalmology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhaoke Ophthalmology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Zhaoke Ophthalmology's EV-to-FCF falls into.



Zhaoke Ophthalmology EV-to-FCF Calculation

Zhaoke Ophthalmology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-532.927/-458.218
=1.16

Zhaoke Ophthalmology's current Enterprise Value is HK$-532.93 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-458.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhaoke Ophthalmology  (HKSE:06622) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Zhaoke Ophthalmology's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.49/-0.776
=At Loss

Zhaoke Ophthalmology's share price for today is HK$1.49.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.776.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Zhaoke Ophthalmology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhaoke Ophthalmology (HKSE:06622) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.
Executives
Mak Siu Hang Viola 2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd 2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd 2101 Beneficial owner
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Fidelity China Special Situations Plc 2101 Beneficial owner
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Vms Holdings Limited 2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited 2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p. 2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p. 2201 Interest of corporation controlled by you

Zhaoke Ophthalmology (HKSE:06622) Headlines

No Headlines